Table 2 Therapeutic classes of treatments purchased by participants (n = 296)
From: Identifying the hidden burden of allergic rhinitis (AR) in community pharmacy: a global phenomenon
| Therapeutic classes | All participants (n = 296) | Self-selected OTC treatment(s) (n = 206) | Consulted with the pharmacist (n = 90) | ||
|---|---|---|---|---|---|
| Product-based request (n = 42) | Symptom-based request (n = 30) | Prescribed treatment (n = 18) | |||
| Purchased Medication | |||||
| Oral Antihistamine | 131 (44.3%) | 93 (45.1%) | 17 (40.5%) | 14 (46.7%) | 7 (38.9%) |
| Intranasal Decongestant | 54 (18.2%) | 39 (18.9%) | 4 (9.5%) | 8 (26.7%) | 3 (16.7%) |
| Intranasal Corticosteroids | 79 (26.7%) | 44 (21.4%) | 15 (35.7%) | 9 (30.0%) | 11 (61.1%) |
| Intranasal Antihistamine | 1 (0.3%) | 1 (0.5%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Saline | 36 (12.2%) | 23 (11.2%) | 7 (16.7%) | 4 (13.3%) | 2 (11.1%) |
| Oral Decongestant | 20 (6.8%) | 14 (6.8%) | 4 (9.5%) | 2 (6.7%) | 0 (0%) |